NCT05221021View on ClinicalTrials.gov

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

PHASE4RecruitingINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

December 30, 2026

Study Completion Date

January 30, 2027

Conditions
Overactive Bladder Syndrome
Interventions
DRUG

Vaginal estrogen

0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill

DRUG

Mirabegron 50 MG [Myrbetriq]

50mg oral Mirabegron once daily

Trial Locations (1)

20889

RECRUITING

Walter Reed National Military Medical Center, Bethesda

All Listed Sponsors
lead

Walter Reed National Military Medical Center

FED